Astrana Health, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K covers events occurring on June 11, 2025, specifically the Company's 2025 Annual Meeting of Stockholders. Astrana Health, Inc. is a Delaware corporation with its principal executive offices in Alhambra, California, and its common stock trades on The Nasdaq Stock Market under the symbol ASTH.
Key Financial Metrics
This filing is a current report regarding corporate governance and equity plan amendments. It does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. Investors should refer to the Company's most recent Form 10-K or 10-Q for financial performance metrics.
Material Changes and Corporate Actions
- Equity Incentive Plan Amendment: Stockholders approved the Amended and Restated 2024 Equity Incentive Plan. The number of shares reserved for issuance was increased by 2,000,000 shares, and the plan term was extended to March 25, 2035.
- Board Elections: Nine directors were elected to serve until the 2026 Annual Meeting. Eight nominees received overwhelming support, while nominee Weili Dai received a majority of "Withheld" votes.
- Accounting Firm Ratification: Ernst & Young LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
- Executive Compensation: The compensation program for named executive officers was approved on an advisory, non-binding basis.
Voting Results and Management Commentary
At the Annual Meeting, 42,924,341 shares were present in person or by proxy, representing approximately 76.6% of the total outstanding eligible votes. The record date was April 22, 2025, with 56,072,504 shares issued and outstanding.
| Proposal | For | Against / Withheld | Abstain | Broker Non-Votes |
|---|---|---|---|---|
| 1. Election of Directors (Aggregate for 8 approved nominees) |
298,600,244 | 6,863,464 | N/A | 38,001,024 |
| 1. Election of Directors (Weili Dai - Not Elected) |
18,977,644 | 19,196,569 | N/A | 4,750,128 |
| 2. Ratification of Auditors | 42,631,420 | 260,880 | 32,041 | 0 |
| 3. Executive Compensation (Say-on-Pay) | 34,713,926 | 3,370,998 | 89,289 | 4,750,128 |
| 4. 2024 Equity Incentive Plan | 36,772,471 | 1,245,886 | 155,856 | 4,750,128 |
Note: The filing does not provide specific management commentary beyond the procedural approval of the proposals.
Key Facts for Investor Verification
- Board Composition Change: Verify the status of Weili Dai, who received more "Withheld" votes than "For" votes, and confirm if the Board has addressed this outcome.
- Dilution Impact: Assess the impact of the additional 2,000,000 shares added to the equity incentive plan on future dilution.
- Plan Terms: Review the full text of the Amended and Restated 2024 Equity Incentive Plan (Exhibit 10.1) for specific vesting schedules and eligibility criteria.
- Financial Data: This 8-K contains no financial performance data; verify current financial health via the latest 10-K or 10-Q filings.